LC-MS/MS-based screening of new protein biomarkers for cervical precancerous lesions and cervical cancer.
10.12122/j.issn.1673-4254.2019.01.03
- Author:
Feng QIU
1
;
Fu CHEN
2
;
Dongdong LIU
2
;
Jianhua XU
2
;
Jingling HE
3
;
Jujiao XIAO
1
;
Longbin CAO
4
;
Xianzhang HUANG
2
Author Information
1. General Practice Center, Nanhai Hospital, Southern Medical University, Foshan 528244, China.
2. Department of Laboratory Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China.
3. Department of Gynecology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China.
4. Department of Laboratory Medicine, Nanhai Hospital, Southern Medical University, Foshan 528244, China.
- Publication Type:Journal Article
- Keywords:
cervical carcinoma;
liquid chromatographytandem mass spectrometry;
proteomics;
serum biomarkers
- MeSH:
Antigens, Neoplasm;
blood;
Biomarkers, Tumor;
blood;
Carrier Proteins;
blood;
Case-Control Studies;
Cervical Intraepithelial Neoplasia;
blood;
diagnosis;
Chromatography, Liquid;
Complement Factor I;
analysis;
Early Detection of Cancer;
Female;
Glycoproteins;
blood;
Haptoglobins;
Humans;
Neoplasm Proteins;
blood;
Orosomucoid;
analysis;
Precancerous Conditions;
blood;
diagnosis;
Serum Albumin, Human;
Tandem Mass Spectrometry;
Uterine Cervical Neoplasms;
blood;
diagnosis
- From:
Journal of Southern Medical University
2019;39(1):13-22
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To screen potential plasma protein biomarkers for the progression of cervical precancerous lesions into cervical carcinoma and analyze their functions.
METHODS:Plasma samples obtained from healthy control subjects, patients with low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), cervical cancer (CC), and patients with CC after treatment were enriched for low-abundance proteins for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The MS data of the samples were analyzed using Discoverer 2.2 software, and the differential proteins (peptide coverage ≥20%, unique peptides≥2) were screened by comparison of LSIL, HSIL and CC groups against the control group followed by verification using target proteomics technology. Protein function enrichment and coexpression analyses were carried out to explore the role of the differentially expressed proteins as potential biomarkers and their pathological mechanisms.
RESULTS:Compared with the control group, both LSIL group and HSIL group showed 9 differential proteins; 5 differentially expressed proteins were identified in CC group. The proteins ORM2 and HPR showed obvious differential expressions in LSIL and HSIL groups compared with the control group, and could serve as potential biomarkers for the progression of cervical carcinoma. The expression of F9 increased consistently with the lesion progression from LSIL to HSIL and CC, suggesting its value as a potential biomarker for the progression of cervical cancer. CFI and AFM protein levels were obviously decreased in treated patients with CC compared with the patients before treatment, indicating their predictive value for the therapeutic efficacy. Protein function enrichment analysis showed that all these differentially expressed proteins were associated with the complement system and the coagulation cascades pathway.
CONCLUSIONS:We identified 5 new protein biomarkers (F9, CFI, AFM, HPR, and ORM2) for cervical precancerous lesions and for prognostic evaluation of CC, and combined detection of these biomarkers may help in the evaluation of the development and progression of CC and also in improving the diagnostic sensitivity and specificity of cervical lesions.
